Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Background High-efficacy therapies in multiple sclerosis are traditionally used after
unsuccessful treatment with first-line disease modifying therapies. We hypothesised that …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Disease-modifying treatments for early and advanced multiple... : Current Opinion in Neurology
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment …

Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

Multiple sclerosis (MS) is a central nervous system (CNS) disorder, which is mediated by an
abnormal immune response coordinated by T and B cells resulting in areas of inflammation …

Background The mechanism of action of oral cladribine, recently licensed for relapsing
multiple sclerosis, is unknown. Objective To determine whether cladribine depletes memory …

Abstract The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with
neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains …